Atea Pharmaceuticals (AVIR) Projected to Announce Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.56) per share and revenue of $33.03 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Atea Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.03. On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Atea Pharmaceuticals Trading Down 1.9%

AVIR opened at $4.61 on Tuesday. Atea Pharmaceuticals has a 1-year low of $2.78 and a 1-year high of $6.45. The stock has a market capitalization of $368.94 million, a price-to-earnings ratio of -2.18 and a beta of 0.29. The business has a 50 day moving average of $4.60 and a 200-day moving average of $4.84.

Hedge Funds Weigh In On Atea Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVIR. Jane Street Group LLC lifted its position in shares of Atea Pharmaceuticals by 80.4% in the 1st quarter. Jane Street Group LLC now owns 102,607 shares of the company’s stock worth $307,000 after acquiring an additional 45,716 shares during the period. Rhumbline Advisers increased its position in shares of Atea Pharmaceuticals by 2.6% during the second quarter. Rhumbline Advisers now owns 119,420 shares of the company’s stock valued at $430,000 after purchasing an additional 2,977 shares during the period. American Century Companies Inc. raised its stake in shares of Atea Pharmaceuticals by 6.7% in the second quarter. American Century Companies Inc. now owns 173,791 shares of the company’s stock valued at $626,000 after purchasing an additional 10,930 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Atea Pharmaceuticals in the second quarter valued at $36,000. Finally, Walleye Capital LLC bought a new position in Atea Pharmaceuticals in the second quarter worth $208,000. 86.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Atea Pharmaceuticals presently has an average rating of “Moderate Buy”.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.